KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

Entries with tag gene .

New Collaboration Opportunities In Regenerative Medicine

New Collaboration Opportunities in Regenerative Medicine and Addressing Challenges to Clinical Adoption of Cell and Gene Therapies New Hunts House Guy’s campus King’s College London London SE1 1UL 14 th June 2016 The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event...
Read More About New Collaboration Opportunities In Regenerative Medicine »

New company created to develop novel technology to treat diabetes

UK technology has potential to bring islet transplant therapy to thousands of patients with type 1 diabetes The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, today announce the creation of Islexa, a new company developing a novel technology to produce laboratory grown islets, the organoids responsible for insulin production. The technology could bring the...
Read More About New company created to develop novel technology to treat diabetes »

New gene therapy for the treatment of children with ultra-rare immune disorder recommended for approval

GlaxoSmithKline has received a thumbs-up from a European Medicines Agency committee for its groundbreaking new gene therapy treatment--but it's already thinking about pricing as it gears up for a final European approval in the coming months. The CHMP--the safety and efficacy arm of the European regulator--recommended approval of GSK's new drug Strimvelis on Friday to treat the incredibly...
Read More About New gene therapy for the treatment of children with ultra-rare immune disorder recommended for approval »

GSK, Miltenyi Biotec form cell and gene therapy alliance

GSK and Miltenyi Biotec have formed a strategic collaboration seeking to optimise the manufacture and delivery of personalised gene therapies.   The UK drugs giant is currently building a cell and gene therapy R&D platform to underpin development of novel therapies in oncology and rare diseases, reflecting its belief in cell and gene therapy’s potential as an important...
Read More About GSK, Miltenyi Biotec form cell and gene therapy alliance »

TrakCel selected for EU CAR-T Cell Therapy Project

TrakCel Ltd., a leading provider of Clinical supply chain orchestration technology for Cell, Gene and Immunotherapies, today announced its selection as a key partner in CARAT, an EU-funded project to support the development of CAR T cell therapies. The CARAT (Chimeric Antigen Receptors (CARs) for Advanced Therapies) project aims to integrate innovative cell manufacturing tools and...
Read More About TrakCel selected for EU CAR-T Cell Therapy Project »

Cell Therapy Catapult is now the Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, announces the official change of its name to the Cell and Gene Therapy Catapult. The new name more accurately reflects the activities of the organisation, the boom in gene modified cell therapies, and...
Read More About Cell Therapy Catapult is now the Cell and Gene Therapy Catapult »

Current Funding Opportunities through EU SME Instrument in support of manufacturing for cell based products

The medical applications of cell technologies include diagnostics and biosensors; cell and gene therapy, tissue engineering, bio-artificial organs, haematology, immunotherapy, and vaccine and antibody production; predictive toxicology, synthetic biology, and modelling development and disease processes. However, the diversity, complexity and variability of living cells pose challenges for...
Read More About Current Funding Opportunities through EU SME Instrument in support of manufacturing for cell based products »

Dawn of gene-editing medicine?

Exceprt from article by BBC health editor James Gallagher  Does the smiling face of Layla Richards mark a new era in genetic medicine that could change all our lives? Her story is simply remarkable and a world first. On the day before her first birthday, Layla's parents were told that all treatments for her leukaemia had failed and she was going to die. The...
Read More About Dawn of gene-editing medicine? »

Encouraging results from the first trial of non-viral based gene therapy for cystic fibrosis

Encouraging results for the study  ' Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial' published buy the Lancet this week Read the full report here
Read More About Encouraging results from the first trial of non-viral based gene therapy for cystic fibrosis »
Showing 9 results.
Items per Page 25
of 1